Resistance to abiraterone in castration-resistant prostate cancer: A review of the literature

Silvana Giacinti, Maria Bassanelli, Anna Maria Aschelter, Annalisa Milano, Michela Roberto, Paolo Marchetti

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Persistent androgen signaling is functionally significant in castration-resistant prostate cancer (CRPC) and it is actually considered a validated therapeutic target. Residual intra-tumoral androgens compensate for the effects of androgen ablation, activating the androgen receptor (AR), AR-mediated gene expression and driving CRPC. The intratumoral biosynthesis of androgens takes place in different ways and cytochrome P450 17A1 (CYP17A1) has a crucial role in this context. Abiraterone, a CYP17A1 inhibitor, has shown impressive results in pre- and post-chemotherapy settings, prolonging the survival of patients with CRPC. However, not all patients respond to the treatment and most responders develop resistance, with a widely variable duration of response. Although many hypotheses are emerging, the mechanisms of resistance to abiraterone treatment have not yet been elucidated. The aim of the present review is to describe the main data currently available on resistance to abiraterone.

Original languageEnglish
Pages (from-to)6265-6269
Number of pages5
JournalAnticancer Research
Volume34
Issue number11
Publication statusPublished - Nov 1 2014

Fingerprint

Castration
Androgens
Prostatic Neoplasms
Androgen Receptors
Cytochrome P-450 Enzyme System
Drug Therapy
Therapeutics
Gene Expression
Survival
abiraterone

Keywords

  • Abiraterone
  • Castration-resistant prostate cancer
  • Prostate cancer
  • Resistance
  • Resistance to abiraterone
  • Review

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Giacinti, S., Bassanelli, M., Aschelter, A. M., Milano, A., Roberto, M., & Marchetti, P. (2014). Resistance to abiraterone in castration-resistant prostate cancer: A review of the literature. Anticancer Research, 34(11), 6265-6269.

Resistance to abiraterone in castration-resistant prostate cancer : A review of the literature. / Giacinti, Silvana; Bassanelli, Maria; Aschelter, Anna Maria; Milano, Annalisa; Roberto, Michela; Marchetti, Paolo.

In: Anticancer Research, Vol. 34, No. 11, 01.11.2014, p. 6265-6269.

Research output: Contribution to journalArticle

Giacinti, S, Bassanelli, M, Aschelter, AM, Milano, A, Roberto, M & Marchetti, P 2014, 'Resistance to abiraterone in castration-resistant prostate cancer: A review of the literature', Anticancer Research, vol. 34, no. 11, pp. 6265-6269.
Giacinti S, Bassanelli M, Aschelter AM, Milano A, Roberto M, Marchetti P. Resistance to abiraterone in castration-resistant prostate cancer: A review of the literature. Anticancer Research. 2014 Nov 1;34(11):6265-6269.
Giacinti, Silvana ; Bassanelli, Maria ; Aschelter, Anna Maria ; Milano, Annalisa ; Roberto, Michela ; Marchetti, Paolo. / Resistance to abiraterone in castration-resistant prostate cancer : A review of the literature. In: Anticancer Research. 2014 ; Vol. 34, No. 11. pp. 6265-6269.
@article{0bd438eb90c94ce8821639ebe796bad7,
title = "Resistance to abiraterone in castration-resistant prostate cancer: A review of the literature",
abstract = "Persistent androgen signaling is functionally significant in castration-resistant prostate cancer (CRPC) and it is actually considered a validated therapeutic target. Residual intra-tumoral androgens compensate for the effects of androgen ablation, activating the androgen receptor (AR), AR-mediated gene expression and driving CRPC. The intratumoral biosynthesis of androgens takes place in different ways and cytochrome P450 17A1 (CYP17A1) has a crucial role in this context. Abiraterone, a CYP17A1 inhibitor, has shown impressive results in pre- and post-chemotherapy settings, prolonging the survival of patients with CRPC. However, not all patients respond to the treatment and most responders develop resistance, with a widely variable duration of response. Although many hypotheses are emerging, the mechanisms of resistance to abiraterone treatment have not yet been elucidated. The aim of the present review is to describe the main data currently available on resistance to abiraterone.",
keywords = "Abiraterone, Castration-resistant prostate cancer, Prostate cancer, Resistance, Resistance to abiraterone, Review",
author = "Silvana Giacinti and Maria Bassanelli and Aschelter, {Anna Maria} and Annalisa Milano and Michela Roberto and Paolo Marchetti",
year = "2014",
month = "11",
day = "1",
language = "English",
volume = "34",
pages = "6265--6269",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "11",

}

TY - JOUR

T1 - Resistance to abiraterone in castration-resistant prostate cancer

T2 - A review of the literature

AU - Giacinti, Silvana

AU - Bassanelli, Maria

AU - Aschelter, Anna Maria

AU - Milano, Annalisa

AU - Roberto, Michela

AU - Marchetti, Paolo

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Persistent androgen signaling is functionally significant in castration-resistant prostate cancer (CRPC) and it is actually considered a validated therapeutic target. Residual intra-tumoral androgens compensate for the effects of androgen ablation, activating the androgen receptor (AR), AR-mediated gene expression and driving CRPC. The intratumoral biosynthesis of androgens takes place in different ways and cytochrome P450 17A1 (CYP17A1) has a crucial role in this context. Abiraterone, a CYP17A1 inhibitor, has shown impressive results in pre- and post-chemotherapy settings, prolonging the survival of patients with CRPC. However, not all patients respond to the treatment and most responders develop resistance, with a widely variable duration of response. Although many hypotheses are emerging, the mechanisms of resistance to abiraterone treatment have not yet been elucidated. The aim of the present review is to describe the main data currently available on resistance to abiraterone.

AB - Persistent androgen signaling is functionally significant in castration-resistant prostate cancer (CRPC) and it is actually considered a validated therapeutic target. Residual intra-tumoral androgens compensate for the effects of androgen ablation, activating the androgen receptor (AR), AR-mediated gene expression and driving CRPC. The intratumoral biosynthesis of androgens takes place in different ways and cytochrome P450 17A1 (CYP17A1) has a crucial role in this context. Abiraterone, a CYP17A1 inhibitor, has shown impressive results in pre- and post-chemotherapy settings, prolonging the survival of patients with CRPC. However, not all patients respond to the treatment and most responders develop resistance, with a widely variable duration of response. Although many hypotheses are emerging, the mechanisms of resistance to abiraterone treatment have not yet been elucidated. The aim of the present review is to describe the main data currently available on resistance to abiraterone.

KW - Abiraterone

KW - Castration-resistant prostate cancer

KW - Prostate cancer

KW - Resistance

KW - Resistance to abiraterone

KW - Review

UR - http://www.scopus.com/inward/record.url?scp=84916206178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84916206178&partnerID=8YFLogxK

M3 - Article

C2 - 25368223

AN - SCOPUS:84916206178

VL - 34

SP - 6265

EP - 6269

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 11

ER -